359 related articles for article (PubMed ID: 27109021)
1. Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals.
Bosutti A; Zanconati F; Grassi G; Dapas B; Passamonti S; Scaggiante B
Anticancer Agents Med Chem; 2016; 16(11):1385-1402. PubMed ID: 27109021
[TBL] [Abstract][Full Text] [Related]
2. The miRNA-kallikrein interaction: a mosaic of epigenetic regulation in cancer.
Di Meo A; Wang C; Cheng Y; Diamandis EP; Yousef GM
Biol Chem; 2018 Sep; 399(9):973-982. PubMed ID: 29604203
[TBL] [Abstract][Full Text] [Related]
3. The epigenetic potentials of dietary polyphenols in prostate cancer management.
Abbas A; Patterson W; Georgel PT
Biochem Cell Biol; 2013 Dec; 91(6):361-8. PubMed ID: 24219277
[TBL] [Abstract][Full Text] [Related]
4. Dietary factors and epigenetic regulation for prostate cancer prevention.
Ho E; Beaver LM; Williams DE; Dashwood RH
Adv Nutr; 2011 Nov; 2(6):497-510. PubMed ID: 22332092
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic regulation of miRNA-cancer stem cells nexus by nutraceuticals.
Ahmad A; Li Y; Bao B; Kong D; Sarkar FH
Mol Nutr Food Res; 2014 Jan; 58(1):79-86. PubMed ID: 24272883
[TBL] [Abstract][Full Text] [Related]
6. Diet, microRNAs and prostate cancer.
Saini S; Majid S; Dahiya R
Pharm Res; 2010 Jun; 27(6):1014-26. PubMed ID: 20221895
[TBL] [Abstract][Full Text] [Related]
7. Resveratrol and pterostilbene as a microRNA-mediated chemopreventive and therapeutic strategy in prostate cancer.
Kumar A; Rimando AM; Levenson AS
Ann N Y Acad Sci; 2017 Sep; 1403(1):15-26. PubMed ID: 28662290
[TBL] [Abstract][Full Text] [Related]
8. Prioritizing candidate disease miRNAs by topological features in the miRNA target-dysregulated network: case study of prostate cancer.
Xu J; Li CX; Lv JY; Li YS; Xiao Y; Shao TT; Huo X; Li X; Zou Y; Han QL; Li X; Wang LH; Ren H
Mol Cancer Ther; 2011 Oct; 10(10):1857-66. PubMed ID: 21768329
[TBL] [Abstract][Full Text] [Related]
9. Detecting microRNAs of high influence on protein functional interaction networks: a prostate cancer case study.
Alshalalfa M; Bader GD; Goldenberg A; Morris Q; Alhajj R
BMC Syst Biol; 2012 Aug; 6():112. PubMed ID: 22929553
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Changes Induced by Green Tea Catechins a re Associated with Prostate Cancer.
Giudice A; Montella M; Boccellino M; Crispo A; D'Arena G; Bimonte S; Facchini G; Ciliberto G; Botti G; Quagliuolo L; Caraglia M; Capunzo M
Curr Mol Med; 2017; 17(6):405-420. PubMed ID: 29256350
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of epi-miRNA expression levels in local/locally advanced and metastatic prostate cancer patients.
Gurbuz V; Kiliccioglu I; Dikmen AU; Bilen CY; Sozen S; Konac E
Gene; 2020 Oct; 758():144963. PubMed ID: 32683077
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic biomarkers in prostate cancer: Current and future uses.
Chiam K; Ricciardelli C; Bianco-Miotto T
Cancer Lett; 2014 Jan; 342(2):248-56. PubMed ID: 22391123
[TBL] [Abstract][Full Text] [Related]
13. Interplay between epigenetic abnormalities and deregulated expression of microRNAs in cancer.
Farooqi AA; Fuentes-Mattei E; Fayyaz S; Raj P; Goblirsch M; Poltronieri P; Calin GA
Semin Cancer Biol; 2019 Oct; 58():47-55. PubMed ID: 30742906
[TBL] [Abstract][Full Text] [Related]
14. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1.
Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Nicoli D; Farnetti E; Santandrea G; Bonacini M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830196
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA mediated therapeutic effects of natural agents in prostate cancer.
Anjaly K; Tiku AB
Mol Biol Rep; 2021 Jul; 48(7):5759-5773. PubMed ID: 34304390
[TBL] [Abstract][Full Text] [Related]
16. DNMT3A epigenetically regulates key microRNAs involved in epithelial-to-mesenchymal transition in prostate cancer.
Mancini M; Grasso M; Muccillo L; Babbio F; Precazzini F; Castiglioni I; Zanetti V; Rizzo F; Pistore C; De Marino MG; Zocchi M; Del Vescovo V; Licursi V; Giurato G; Weisz A; Chiarugi P; Sabatino L; Denti MA; Bonapace IM
Carcinogenesis; 2021 Dec; 42(12):1449-1460. PubMed ID: 34687205
[TBL] [Abstract][Full Text] [Related]
17. Nutrition and prostate cancer: an overview.
Patel VH
Expert Rev Anticancer Ther; 2014 Nov; 14(11):1295-304. PubMed ID: 25367323
[TBL] [Abstract][Full Text] [Related]
18. Missing link between microRNA and prostate cancer.
Gill BS; Alex JM; Navgeet ; Kumar S
Tumour Biol; 2016 May; 37(5):5683-704. PubMed ID: 26822307
[TBL] [Abstract][Full Text] [Related]
19. The Crosstalk of Long Non-Coding RNA and MicroRNA in Castration-Resistant and Neuroendocrine Prostate Cancer: Their Interaction and Clinical Importance.
Hu CY; Wu KY; Lin TY; Chen CC
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008817
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1.
Ramalho-Carvalho J; Martins JB; Cekaite L; Sveen A; Torres-Ferreira J; Graça I; Costa-Pinheiro P; Eilertsen IA; Antunes L; Oliveira J; Lothe RA; Henrique R; Jerónimo C
Cancer Lett; 2017 Jan; 385():150-159. PubMed ID: 27984115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
